![Heng Xie](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Heng Xie worked as a Director at Beijing Biostar Pharmaceuticals Co. Ltd.
in 2022.
Prior to that, he obtained a doctorate degree from The University of Alabama at Birmingham in 1997.
Eerdere bekende functies van Heng Xie
Bedrijven | Functie | Einde |
---|---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
![]() Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Directeur/Bestuurslid | 01-06-2022 |
Opleiding van Heng Xie
The University of Alabama at Birmingham | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
![]() Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Health Technology |